author-photo

Angelo Martignetti

Academy for Urban School Leadership

23

Papers

261

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.

2021 Clinical Colorectal Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Registro osservazionale REGBEV: Analisi dei risultati clinici di Bevacizumab in combinazione con chemioterapia nella prima linea del carcinoma colon-retto metastico

2020
Show All
- Source
- Cite
- Save
Citations (0)
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors

2019 Cancers
Show All
- Source
- Cite
- Save
Citations (9)
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial

2019 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (11)
Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers

2019
Show All
- Source
- Cite
- Save
Citations (0)
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (52)
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer

2018
Show All
- Source
- Cite
- Save
Citations (13)
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

2017 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (17)
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2−) metastatic breast cancer (mBC) (TREnd trial).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)